Relmada Therapeutics, Inc. (RLMD) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Coral Gables, FL, 美国. 现任CEO为 Sergio Traversa.
RLMD 拥有 IPO日期为 2014-06-20, 17 名全职员工, 在 NASDAQ Global Select, 市值为 $527.27M.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
